NeoGenomics, Inc. (NEO)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy limit 15.88 on a retest of the 8/3 close-8/4 open support zone; stop 15.17 below the 3-session swing low, targets 17.56 and 18.82, R/R 2.37.
Company overview
NeoGenomics, Inc. provides cancer-focused diagnostic and testing services through laboratories in the U.S., Europe, and Asia. It operates Clinical and Pharma Services divisions, offering cytogenetics, FISH, flow cytometry, immunohistochemistry, and molecular testing. The company supports pharmaceutical oncology programs and acts as a reference laboratory for anatomic pathology testing.
Fundamental
fairNeoGenomics shows revenue growth but faces profitability challenges and regulatory risks.
Revenue has been growing (FY2025 $727.3M; ~10.70% 5-year CAGR) but FY2025 remained materially loss-making (net margin -14.85%, EBITDA margin -5.32%). SEC filings indicate adequate near-term liquidity and improving 2026 trends, but reimbursement/regulatory + legal/compliance risks and an ongoing profitability turnaround keep fundamentals mixed → fundamentalScore 3.
Sentiment
fairRecent Q2 results drive sentiment, but legal overhangs and minimal retail engagement limit momentum.
Near-term narrative is driven by the Q2’26 earnings/guidance update (announced 2026-07-28), with in-window media tone leaning bullish and modestly stronger than the 30–90d baseline (baseline coverage required aggregator sources). Red-Flag Screen shows no severe investigations, but recent DOJ/OIG settlement headlines (announced 2026-07-20) remain a residual overhang, keeping conviction at a 3.
Technical
goodThe stock is in a confirmed uptrend, with a pullback entry preferred over chasing current highs.
NEO is in a confirmed short-term uptrend: price is above SMA20/50/200, EMA9/21 and the latest daily VWAP, while MACD stays positive above both signal and zero. RSI14 at 63.31 and ADX14 at 46.31 confirm momentum and trend strength, but Williams %R at -1.67 shows the stock is stretched near the high, so the cleaner edge is to buy a retest of support rather than chase the close.
You’re looking at 2026-08-05 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.